results with median follow-up of 14.3 months presented atESMO Congress 2025showed ORR continued to increase over time among patients treated with pimicotinib from the beginning of the study.

TGCT is a rare, locally aggressive tumor occurring in or around the joint leading to progressive swelling, stiffness and reduced mobility of the affected joint, significantly impacting daily activities and quality of life in what is typically an otherwise healthy population. If left untreated or in recurrent cases, TGCT may result in irreversible damage to the bone, joint and surrounding tissues. A significant need remains for highly effective and well-tolerated treatments beyond surgery that can not only shrink tumors but also alleviate pain and restore function.

In December 2025, pimicotinib wasapproved by the China National Medical Products Administration (NMPA)for the treatment of adult patients with symptomatic TGCT for which surgical resection will potentially cause funct
=*=*=*=*=*=
当前为第3/7页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页